Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Ticker
$ARCT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
175
ISIN
US03969T1097
Website
ARCT Metrics
BasicAdvanced
$401M
-
-$2.52
2.37
-
Price and volume
Market cap
$401M
Beta
2.37
52-week high
$25.54
52-week low
$8.04
Average daily volume
510K
Financial strength
Current ratio
5.643
Quick ratio
4.686
Long term debt to equity
16.678
Total debt to equity
18.249
Profitability
EBITDA (TTM)
-78.642
Gross margin (TTM)
-22.83%
Net profit margin (TTM)
-47.47%
Operating margin (TTM)
-57.13%
Effective tax rate (TTM)
0.54%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-13.67%
Return on equity (TTM)
-27.40%
Valuation
Price to revenue (TTM)
2.785
Price to book
1.72
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
-4.453
Free cash flow yield (TTM)
-22.46%
Free cash flow per share (TTM)
-332.16%
Growth
Revenue change (TTM)
15.38%
Earnings per share change (TTM)
-37.27%
3-year revenue growth (CAGR)
110.17%
3-year earnings per share growth (CAGR)
-30.56%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
Bulls say / Bears say
Arcturus Therapeutics received Fast Track Designation from the U.S. FDA for its self-amplifying mRNA vaccine candidate ARCT-2304 targeting pandemic influenza A virus H5N1, potentially expediting its development and review process. (arcturusrx.com)
The European Commission approved KOSTAIVE®, the first self-amplifying mRNA COVID-19 vaccine developed by Arcturus and CSL, marking a significant advancement in vaccine technology. (arcturusrx.com)
BTIG Research initiated coverage of Arcturus Therapeutics with a 'Buy' rating and a $41.00 price target, indicating strong confidence in the company's growth prospects. (defenseworld.net)
Arcturus reported a net loss of $30.0 million ($1.11 per share) in Q4 2024, reflecting ongoing financial challenges. (arcturusrx.com)
The company's Q4 2024 revenues declined to $22.8 million from $30.9 million in Q4 2023, indicating a downward trend in revenue generation. (arcturusrx.com)
Despite positive developments, the stock price remains volatile, with a recent closing price of $13.78, significantly below analyst price targets, suggesting market skepticism. (finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
ARCT News
AllArticlesVideos
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Business Wire·1 week ago
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Business Wire·2 weeks ago
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $401M as of July 10, 2025.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of July 10, 2025.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.